| Literature DB >> 30380600 |
Josivan da Silva Costa1,2,3, Ryan da Silva Ramos4,5, Karina da Silva Lopes Costa6, Davi do Socorro Barros Brasil7, Carlos Henrique Tomich de Paula da Silva8, Elenilze Figueiredo Batista Ferreira9, Rosivaldo Dos Santos Borges10, Joaquín María Campos11, Williams Jorge da Cruz Macêdo12,13, Cleydson Breno Rodrigues Dos Santos14,15,16.
Abstract
The antioxidant activity of molecules constitutes an important factor for the regulation of redox homeostasis and reduction of the oxidative stress. Cells affected by oxidative stress can undergo genetic alteration, causing structural changes and promoting the onset of chronic diseases, such as cancer. We have performed an in silico study to evaluate the antioxidant potential of two molecules of the zinc database: ZINC08706191 (Z91) and ZINC08992920 (Z20). Molecular docking, quantum chemical calculations (HF/6-31G**) and Pearson's correlation have been performed. Molecular docking results of Z91 and Z20 showed both the lower binding affinity (BA) and inhibition constant (Ki) values for the receptor-ligand interactions in the three tested enzymes (cytochrome P450-CP450, myeloperoxidase-MP and NADPH oxidase-NO) than the control molecules (5-fluorouracil-FLU, melatonin-MEL and dextromethorphan-DEX, for each receptor respectively). Molecular descriptors were correlated with Ki and strong correlations were observed for the CP450, MP and NO receptors. These and other results attest the significant antioxidant ability of Z91 and Z20, that may be indicated for further analyses in relation to the control of oxidative stress and as possible antioxidant agents to be used in the pharmaceutical industry.Entities:
Keywords: antioxidant potential; binding free energy; free radicals; molecular descriptors; molecular docking; oxidative stress
Mesh:
Substances:
Year: 2018 PMID: 30380600 PMCID: PMC6278550 DOI: 10.3390/molecules23112801
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Data obtained in the validation of the molecular docking protocols for the receptors cytochrome P450 (CP450), lypoxygenase (LO), myeloperoxidase (MP), NADPH oxidase (NO) and xanthine oxidase (XO).
Figure 2Binding free energy values resulting from the molecular docking between the molecules and receptors evaluated. Control molecules for CP450, LO, MP, NO and XO were 5-fluorouracil (FLU), zileuton (ZIL), melatonin (MEL), dextromethorphan (DEX) and febuxostat (FEB), respectively.
Figure 3Binding affinity provided by AutoDock/Vina software of the tested molecules (Z20 and Z91). Control 1/Control 2 molecules for CP450, LO, MP, NO and XO were FLU/S-warfarin, ZIL/protocatechuic acid, MEL/N-acetyl-D-glucosamine, DEX/adenosine-5’-diphosphate and FEB/hypoxanthine, respectively.
Figure 4Interactions of the tested molecules (Z20 and Z91) and control (FLU) with the CP450 receptor. In A, interactions common to the three ligands (blue), two ligands (green) and interactions presented by a single ligand (yellow) are presented. Hydrogen bond (A); carbon-hydrogen bond (B); pi-sigma (C); pi-alkyl (D); alkyl (E).
Figure 5Interactions of the tested molecules (Z20 and Z91) and control (MEL) with the MP receptor. In A, interactions common to the three ligands (blue) and two ligands (green). Hydrogen bond (A); carbon-hydrogen bond (B); pi-sigma (C); pi-alkyl (D); alkyl (E).
Figure 6Interactions of the tested molecules (Z20 and Z91) and control (DEX) with the NO receptor. In A, interactions common to the three ligands (blue), two ligands (green) and interactions presented by a single ligand (yellow) are presented. Hydrogen bond (A); carbon-hydrogen bond (B); pi-sigma (C); pi-alkyl (D); akyl (E).
Structure of the tested molecules used for in silico evaluation of the antioxidant potential.
| Molecule | Assignment |
|---|---|
|
| Tested molecule |
|
| Tested molecule |
Molecular descriptors of the tested (Z20 and Z91) and reference molecules (5-fluorouracil—FLU, melatonin—MEL and dextromethorphan) and their correlations (CKi-CP450, CKi-MP and CKi-NO) with Ki values resulting from the molecular docking study.
|
|
|
|
|
|
|
| AST (Å2) | 457.6300 | 432.0800 | 229.5500 | 438.0500 | 371.1200 |
| MV (Å3) | 831.4000 | 817.9600 | 348.7100 | 740.5100 | 821.6600 |
| χ (eV) | 2.9553 | 2.9776 | 3.5946 | 1.9003 | 1.9594 |
| η (eV) | 5.2982 | 5.3058 | 6.3539 | 5.4811 | 5.9292 |
| 1/η (eV) | 0.1887 | 0.1885 | 0.1574 | 0.1824 | 0.1687 |
| μ (eV) | −2.9553 | −2.9776 | −3.5946 | −1.9003 | −1.9594 |
| Ki-CP450 (µM) | 24.30 | 17.89 | 182.0 | - | - |
| Ki-MP (µM) | 22.58 | 19.97 | - | 185.0 | - |
| Ki-NO (µM) | 9.83 | 3.36 | - | - | 7.11 |
|
|
|
|
|
|
|
| AST | −0.95 | −0.28 | −0.51 | - | - |
| VM | −0.99 | −0.05 | −0.74 | - | - |
| χ | −0.67 | −0.60 | −0.08 | - | - |
| η | 0.85 | 0.19 | 0.49 | - | - |
| 1/η | −0.83 | −0.17 | −0.48 | - | - |
| μ | −0.67 | −0.60 | −0.08 | - | - |
Å = Angstrom; eV = eletron volt. Significant data at p < 0.05.
Representations of the molecular orbitals and their GAP values (energy variation between frontier orbitals—HOMO and LUMO) between all energy states ([a] GAP1, [b] GAP2, [c] GAP3 and [d] GAP4) of the Z20, Z91, 5-fluorouracil (FLU), melatonin (MEL) and dextromethorphan (DEX).
|
|
|
|
|
|
|
|
|
|
|
|
| GAP1 = 10.6116 eV | GAP2 = 12.6035 eV | GAP3 = 11.7711 eV | GAP4 = 13.7630 eV | |
|
|
|
|
|
|
| GAP1 = 10.5964 eV | GAP2 = 12.5932 eV | GAP3 = 11.7572 eV | GAP4 = 13.7540 eV | |
|
|
|
|
|
|
| GAP1 = 12.7077 eV | GAP2 = 14.8923 eV | GAP3 = 14.7945 eV | GAP4 = 16.9791 eV | |
|
|
|
|
|
|
| GAP1 = 10.9621 eV | GAP2 = 12.6495 eV | GAP3 = 11.2799 eV | GAP4 = 12.9853 eV | |
|
|
|
|
|
|
| GAP1 = 11.8585 eV | GAP2 = 12.4686 eV | GAP3 = 12.4479 eV | GAP4 = 13.3285 eV |
[a] GAP1 = LUMO − HOMO; [b] GAP2 = LUMO+1 − HOMO; [c] GAP3 =LUMO − HOMO-1; [d] GAP4 = LUMO+1 − HOMO-1.
Correlations between molecular orbitals data and Ki values.
| Descriptors | Enzymes | ||
|---|---|---|---|
| CP450 | MP | NO | |
| HOMO-1 (eV) | −0.38 | −0.81 | −0.92 |
| HOMO (eV) | −0.13 | −0.47 | −0.22 |
| LUMO (eV) | 0.91 | 0.54 | 0.30 |
| LUMO+1 (eV) | 0.88 | 0.60 | 0.23 |
Variations of GAP values compared to controls.
| ΔGAP | GAP1 * | GAP2 * | GAP3 * | GAP4 * |
|---|---|---|---|---|
| ΔGAP (Z20-FLU) | −2.0961 | −2.2888 | −3.0234 | −3.2161 |
| ΔGAP (Z91-FLU) | −2.1113 | −2.2991 | −3.0373 | −3.2251 |
| ΔGAP (Z20-MEL) | −0.3505 | −0.3586 | 0.4912 | 0.7777 |
| ΔGAP (Z91-MEL) | −0.3657 | −0.3689 | 0.4773 | 0.7687 |
| ΔGAP (Z20-DEX) | −1.2469 | 0.1349 | −0.6768 | 0.4345 |
| ΔGAP (Z91-DEX) | −1.2621 | 0.1246 | −0.6907 | 0.4255 |
* Tested molecule GAP—Control GAP.
Data from protocols used in the molecular docking validation.
| Receptor | Ligand | Coordinates of the Grid Center | Grid Size (points) |
|---|---|---|---|
| CP450 | −20.257x | 22 x | |
| LO | Protocatecuic acid | 21.864x | 24 x |
| MP | N-Acetyl-D-glucosamine | 39.817x | 22 x |
| NO | Adenosine-5’-diphosphate | 1.687x | 30 x |
| XO | Hypoxanthine | 89.018x | 37 x |
Structure of the controls molecules used for in silico evaluation of the antioxidant potential.
| Molecule | Assignment |
|---|---|
|
| Molecule (control) present in commercially available drug with inhibitory activity at the CP450 receptor [ |
|
| Molecule (control) present in commercially available drug with inhibitory activity at the LO receptor [ |
|
| Molecule (control) present in commercially available drug with inhibitory activity at the MP receptor [ |
|
| Molecule (control) present in commercially available drug with inhibitory activity at the NO receptor [ |
|
| Molecule (control) present in commercially available drug with inhibitory activity at the XO receptor [ |